Serum BAFF Levels, Methypredsinolone Therapy, Epstein-Barr Virus and Mycobacterium Avium Subsp. Paratuberculosis Infection in Multiple Sclerosis Patients

Overview

Journal Sci Rep

Specialty Science

Date 2016 Jul 8

PMID 27383531

Citations 8

Authors

Giuseppe Mameli

Eleonora Cocco

Jessica Frau

Giannina Arru

Elisa Caggiu

Maria Giovanna Marrosu

Leonardo A Sechi

Affiliations

Soon will be listed here.

Abstract

Elevated B lymphocyte activating factor BAFF levels have been reported in multiple sclerosis (MS) patients; moreover, disease-modifying treatments (DMT) have shown to influence blood BAFF levels in MS patients, although the significance of these changes is still controversial. In addition, BAFF levels were reported increased during infectious diseases. In our study, we wanted to investigate on the serum BAFF concentrations correlated to the antibody response against Mycobacterium avium subspecies paratuberculosis (MAP), Epstein-Barr virus (EBV) and their human homologous epitopes in MS and in patients affected with other neurological diseases (OND), divided in Inflammatory Neurological Diseases (IND), Non Inflammatory Neurological Diseases (NIND) and Undetermined Neurological Diseases (UND), in comparison to healthy controls (HCs). Our results confirmed a statistically significant high BAFF levels in MS and IND patients in comparison to HCs but not NIND and UND patients. Interestingly, BAFF levels were inversely proportional to antibodies level against EBV and MAP peptides and the BAFF levels significantly decreased in MS patients after methylprednisolone therapy. These results implicate that lower circulating BAFF concentrations were present in MS patients with humoral response against MAP and EBV. In conclusion MS patients with no IgGs against EBV and MAP may support the hypothesis that elevated blood BAFF levels could be associated with a more stable disease.

Citing Articles

Role of serum B-cell-activating factor and interleukin-17 as biomarkers in the classification of interstitial pneumonia with autoimmune features.

Zhao L, Liu L, Liu Y, Zheng H, Jiang P Open Life Sci. 2024; 19(1):20220814.

PMID: 38465342 PMC: 10921473. DOI: 10.1515/biol-2022-0814.

Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum.

Berek K, Bauer A, Rudzki D, Auer M, Barket R, Zinganell A Front Immunol. 2023; 14:1200146.

PMID: 37383229 PMC: 10294231. DOI: 10.3389/fimmu.2023.1200146.

Circulating Memory B Cells in Early Multiple Sclerosis Exhibit Increased IgA Cells, Globally Decreased BAFF-R Expression and an EBV-Related IgM Cell Signature.

Leffler J, Trend S, Ward N, Grau G, Hawke S, Byrne S Front Immunol. 2022; 13:812317.

PMID: 35250986 PMC: 8888440. DOI: 10.3389/fimmu.2022.812317.

Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression.

Perez-Perez S, Dominguez-Mozo M, Garcia-Martinez M, Garcia-Frontini M, Villarrubia N, Costa-Frossard L Front Immunol. 2021; 12:798003.

PMID: 34912348 PMC: 8666430. DOI: 10.3389/fimmu.2021.798003.

A Comparative Study on the Efficiency of Two subsp. (MAP)-Derived Lipopeptides of L3P and L5P as Capture Antigens in an In-House Milk ELISA Test.

Hosseiniporgham S, Biet F, Ganneau C, Bannantine J, Bay S, Sechi L Vaccines (Basel). 2021; 9(9).

PMID: 34579234 PMC: 8471605. DOI: 10.3390/vaccines9090997.

References

Nduati E, Gwela A, Karanja H, Mugyenyi C, Langhorne J, Marsh K . The plasma concentration of the B cell activating factor is increased in children with acute malaria. J Infect Dis. 2011; 204(6):962-70. PMC: 3156925. DOI: 10.1093/infdis/jir438. View

Cossu D, Mameli G, Galleri G, Cocco E, Masala S, Frau J . Human interferon regulatory factor 5 homologous epitopes of Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis induce a specific humoral and cellular immune response in multiple sclerosis patients. Mult Scler. 2014; 21(8):984-95. DOI: 10.1177/1352458514557304. View

Gasperi C, Stuve O, Hemmer B . B cell-directed therapies in multiple sclerosis. Neurodegener Dis Manag. 2016; 6(1):37-47. DOI: 10.2217/nmt.15.67. View

Rickert R, Jellusova J, Miletic A . Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011; 244(1):115-33. PMC: 3202302. DOI: 10.1111/j.1600-065X.2011.01067.x. View

Polman C, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302. PMC: 3084507. DOI: 10.1002/ana.22366. View

Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y . Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun. 2006; 27(2):134-9. DOI: 10.1016/j.jaut.2006.07.005. View

Kannel K, Alnek K, Vahter L, Gross-Paju K, Uibo R, Kisand K . Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. PLoS One. 2015; 10(11):e0143393. PMC: 4658115. DOI: 10.1371/journal.pone.0143393. View

Dickinson G, Akkoyunlu M, Bram R, Alugupalli K . BAFF receptor and TACI in B-1b cell maintenance and antibacterial responses. Ann N Y Acad Sci. 2015; 1362:57-67. DOI: 10.1111/nyas.12772. View

Sechi L, Dow C . Mycobacterium avium ss. paratuberculosis Zoonosis - The Hundred Year War - Beyond Crohn's Disease. Front Immunol. 2015; 6:96. PMC: 4349160. DOI: 10.3389/fimmu.2015.00096. View

10.

Frau J, Cossu D, Coghe G, Lorefice L, Fenu G, Melis M . Mycobacterium avium subsp. paratuberculosis and multiple sclerosis in Sardinian patients: epidemiology and clinical features. Mult Scler. 2013; 19(11):1437-42. DOI: 10.1177/1352458513477926. View

11.

Krumbholz M, Faber H, Steinmeyer F, Hoffmann L, Kumpfel T, Pellkofer H . Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain. 2008; 131(Pt 6):1455-63. DOI: 10.1093/brain/awn077. View

12.

Cossu D, Masala S, Sechi L . A Sardinian map for multiple sclerosis. Future Microbiol. 2013; 8(2):223-32. DOI: 10.2217/fmb.12.135. View

13.

Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B . Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol. 2011; 188(1):497-503. DOI: 10.4049/jimmunol.1102321. View

14.

Vaknin-Dembinsky A, Brill L, Orpaz N, Abramsky O, Karussis D . Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Mult Scler. 2010; 16(12):1453-7. DOI: 10.1177/1352458510380416. View

15.

Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu C . BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005; 201(2):195-200. PMC: 2212784. DOI: 10.1084/jem.20041674. View

16.

Caro-Maldonado A, Wang R, Nichols A, Kuraoka M, Milasta S, Sun L . Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol. 2014; 192(8):3626-36. PMC: 3984038. DOI: 10.4049/jimmunol.1302062. View

17.

Mameli G, Cossu D, Cocco E, Masala S, Frau J, Marrosu M . EBNA-1 IgG titers in Sardinian multiple sclerosis patients and controls. J Neuroimmunol. 2013; 264(1-2):120-2. DOI: 10.1016/j.jneuroim.2013.07.017. View

18.

Lehmann-Horn K, Kronsbein H, Weber M . Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord. 2013; 6(3):161-73. PMC: 3625013. DOI: 10.1177/1756285612474333. View

19.

Bornacelly A, Mercado D, Acevedo N, Caraballo L . The strength of the antibody response to the nematode Ascaris lumbricoides inversely correlates with levels of B-Cell Activating Factor (BAFF). BMC Immunol. 2014; 15:22. PMC: 4067067. DOI: 10.1186/1471-2172-15-22. View

20.

Franciotta D, Di Stefano A, Jarius S, Zardini E, Tavazzi E, Ballerini C . Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J Neuroimmunol. 2010; 230(1-2):160-3. DOI: 10.1016/j.jneuroim.2010.10.027. View